A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CHRONOS3
- Sponsors Ipsen
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 13 Feb 2019 Planned primary completion date changed from 1 May 2018 to 1 Jun 2019.
- 12 Jul 2018 Planned End Date changed from 1 May 2019 to 1 Jun 2019.